FDA accepts Teva's application for Uzedy for bipolar I disorder
Teva (NYSE:TEVA) will be responsible for potential commercialization of Uzedy for BP-I. Medincell will be eligible for ...
Pharmabiz1 个月
Teva Pharma, Medincell announce US FDA acceptance of sNDA for Uzedy to treat people living ...
Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd, and Medincell announced that the supplemental New Drug Application (sNDA) for Uzedy extended-release injectable suspension ...